New treatment options for vitiligo
Official title: Novel Small Molecule Therapeutic for Vitiligo
Funded at Aohbio Corporation · NIH-11005527 · Data updated 2026-11-12
This study is looking at a new treatment for vitiligo, a condition that causes skin to lose its color, by targeting a specific protein that plays a role in the disease, with the goal of finding effective and affordable options to help improve the lives of people with vitiligo.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aohbio Corporation NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project start | September 10, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $306,278 |
| NIH project number | 1R41AR084965-01 |
| Project ID | NIH-11005527 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with vitiligo who are seeking new treatment options.
✕Less likely to help
Patients who do not have vitiligo or those who have already found effective treatments may not benefit from this research.
What this research studies
This research focuses on developing a novel small molecule therapeutic aimed at treating vitiligo, a condition that causes patchy loss of skin pigmentation. The approach involves investigating the autoimmune mechanisms behind vitiligo, particularly the role of the cytokine CXCL10, which is found at high levels in affected skin. By inhibiting the signaling pathways that lead to CXCL10 expression, the researchers aim to create effective and affordable treatments that can improve the quality of life for patients with vitiligo. The research will utilize both murine models and human tissue to test the efficacy of these new compounds.
Why it matters
Potential benefit: If successful, this research could provide a new, effective, and cost-efficient treatment option for individuals suffering from vitiligo.
How similar studies have gone: While there is limited research on small molecule therapeutics for vitiligo, the approach of targeting CXCL10 has shown promise in preliminary studies.
Where this research is happening
-
Aohbio Corporation
Athens, United States Active
Researchers
- Principal investigator: Mccall, Kelly — Aohbio Corporation
- Study coordinator: Mccall, Kelly
Related research
Other NIH-funded projects on the same topics.
-
Cell communications and tissue memory in vitiligo
This grant looks at how skin cells talk to each other and how these conversations may drive vitiligo, with the goal of finding new ways to treat or manage the condition.
-
Autoreactive T Cell Function in Vitiligo
A study in people with vitiligo and related models aims to understand how skin-homing T cells drive pigment loss and how this knowledge could lead to better treatments.
-
Understanding why the immune system targets skin in vitiligo and how this causes lasting damage
A research program is studying how immune cells attack pigment cells in the skin of people with vitiligo and what drives this autoimmune process.
-
Understanding why some vitiligo patches repigment while others stay white
This grant studies why certain vitiligo patches repigment in some areas after treatment and why others persist, aiming to make treatments faster and more even.
-
Understanding Cell Communication and Tissue Memory in Vitiligo
This project aims to understand how skin cells communicate and remember past events in people with vitiligo, hoping to find new ways to treat the condition.
-
Understanding T Cells in Vitiligo
This research explores how certain immune cells, called T cells, cause the skin condition vitiligo, which leads to white spots on the skin.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.